Literature DB >> 19233195

Impact of glucose concentration on cardiac ventricular repolarization under I Kr/I Ks blocking agents.

Raymond Hreiche1, Isabelle Plante, Louis-Philippe David, Chantale Simard, Jacques Turgeon, Benoit Drolet.   

Abstract

Drug-induced QT interval prolongation is a condition likely to be aggravated by diabetes. The objective of this study was to evaluate how glucose concentration may modulate drug effects on ventricular repolarization and on cardiac repolarizing potassium currents. Guinea pig hearts were Langendorff-retroperfused and monophasic action potential duration (MAPD) was measured. Glucose (1, 5 or 20 mmol/L) was tested with either dofetilide (a specific I(Kr) blocker), chromanol 293B (a specific I(Ks) blocker) or both. Effects of glucose (1, 5 or 20 mmol/L) on I(Kr) blockade mediated by dofetilide were also measured in HERG-transfected HEK293 cells in the absence vs presence of the P-glycoprotein drug transporter, using the whole cell patch-clamp technique. Our results suggest that both hypo- and hyperglycemia potentiate the MAPD-prolonging and I(Kr)-blocking properties of dofetilide. P-glycoprotein drug extrusion efficacy appears as a key determinant of dofetilide's I(Kr)-blocking effect. This efficacy appears to be affected by glucose concentration, particularly hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233195     DOI: 10.1016/j.yjmcc.2009.02.004

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

1.  Intracellular Binding of Terfenadine Competes with Its Access to Pancreatic ß-cell ATP-Sensitive K+ Channels and Human ether-à-go-go-Related Gene Channels.

Authors:  Bernd J Zünkler; Maria Wos-Maganga; Stefanie Bohnet; Anne Kleinau; Detlef Manns; Shivani Chatterjee
Journal:  J Membr Biol       Date:  2022-06-28       Impact factor: 1.843

2.  Hyperglycemia is associated with corrected QT prolongation and mortality in acutely ill patients.

Authors:  David Pickham; Elena Flowers; Barbara J Drew
Journal:  J Cardiovasc Nurs       Date:  2014 May-Jun       Impact factor: 2.083

3.  Inter-individual variability and modeling of electrical activity: a possible new approach to explore cardiac safety?

Authors:  Jean-Yves Le Guennec; Jérôme Thireau; Aude Ouillé; Julien Roussel; Jérôme Roy; Serge Richard; Sylvain Richard; Eric Martel; Pascal Champéroux
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

4.  Usefulness of simultaneous and sequential monitoring of glucose level and electrocardiogram in monkeys treated with gatifloxacin under conscious and nonrestricted conditions.

Authors:  Yu Yoshimatsu; Tomomichi Ishizaka; Katsuyoshi Chiba; Kazuhiko Mori
Journal:  Exp Anim       Date:  2018-01-03

5.  Selective protein kinase C inhibition switches time-dependent glucose cardiotoxicity to cardioprotection.

Authors:  Sean Brennan; Simona Esposito; Muhammad I M Abdelaziz; Christopher A Martin; Samir Makwana; Mark W Sims; Iain B Squire; Parveen Sharma; Amy E Chadwick; Richard D Rainbow
Journal:  Front Cardiovasc Med       Date:  2022-09-07

6.  Effect of hyperglycaemia in combination with moxifloxacin on cardiac repolarization in male and female patients with type I diabetes.

Authors:  Jorg Taubel; Dominic Pimenta; Samuel Thomas Cole; Claus Graff; Jørgen K Kanters; A John Camm
Journal:  Clin Res Cardiol       Date:  2022-05-21       Impact factor: 6.138

7.  Distinct and complementary roles for α and β isoenzymes of PKC in mediating vasoconstrictor responses to acutely elevated glucose.

Authors:  Robert Jackson; Sean Brennan; Peter Fielding; Mark W Sims; R A John Challiss; David Adlam; Iain B Squire; Richard D Rainbow
Journal:  Br J Pharmacol       Date:  2016-02-08       Impact factor: 8.739

8.  Sevoflurane causes greater QTc interval prolongation in chronically hyperglycemic patients than in normoglycemic patients.

Authors:  Seishi Kimura; Shinichi Nakao; Atsuhiro Kitaura; Tatushige Iwamoto; Kei Houri; Mayuka Matsushima; Shinichi Hamasaki
Journal:  PLoS One       Date:  2017-12-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.